Dori A Thomas-Karyat
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2020First federal award
$2.5MFederal grants as PI4 awards
3Patents grantedLatest Nov 18, 2025
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
4 awards · $2.5M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jun 11, 2025 | NIH | SBIR Phase II In vivo efficacy, safety and PK/PD analysis of SYN101, a first in class, immune cell targeted TGFb therapy for cancer patients | $1.4M | Synthis Therapeutics, Inc. |
| Sep 18, 2024 | NIH | SBIR Phase II In vivo efficacy, safety and PK/PD analysis of SYN101, a first in class, immune cell targeted TGFb therapy for cancer patients | $579K | Synthis Therapeutics, Inc. |
| May 8, 2023 | NIH | SBIR Phase I Development of a targeted TGF-b therapeutic that selectively blocks lung fibrosis in idiopathic pulmonary fibrosis (IPF) patients | $300K | Synthis Therapeutics, Inc. |
| Jul 10, 2020 | NIH | SBIR Phase I Development of a novel checkpoint inhibitor-TGF beta combination therapy to reverse immune suppression and increase survival rates in advanced colorectal cancer patients | $210K | Synthis Therapeutics, Inc. |
4 patents as inventor
- US 11583593Synthis Therapeutics, Inc.Feb 21, 2023
- US 11987558Synthis Therapeutics, Inc.May 21, 2024
- US 12473377Synthis Therapeutics, Inc.Nov 18, 2025
- US Synthis Therapeutics, Inc.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#764
Awards as PI#566
Patents#63
Companies
- Synthis Therapeutics, Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.